Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
50 results about "Oestrogen deficiency" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hypoestrogenism, or estrogen deficiency, refers to a lower than normal level of estrogen, the primary sex hormone in women. In general, lower levels of estrogen may cause differences in the breasts, genitals, urinary tract, and skin.
Compositions of unconjugated estrogens and methods for their use
InactiveUS20060183724A1Improve efficacyImprovement of side effectsOrganic active ingredientsBiocidePhysiologyOestrogen deficiency
The present invention relates to compositions containing unconjugated estrogens and methods of their use in the treatment of conditions associated with hypoestrogenism or reduced estrogen levels in females.
Owner:DURAMED PHARMA
Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ActiveUS8026228B2Suppress ovarian estrogenAvoid symptomsBiocideOrganic active ingredientsPresent methodMammal
One aspect of the present invention relates to a method of hormone replacement in mammals, which method comprises the oral administration of an estrogenic component and a progestogenic component to a mammal in an effective amount to prevent or treat symptoms of hypoestrogenism, wherein the estrogenic component is selected from the group consisting of substances represented by the above formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; and no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and / or precursors. Another aspect of the invention concerns a pharmaceutical kit comprising oral dosage units that contain the aforementioned estrogenic component and a progestogenic component as well as an androgenic component.
Owner:ESTETRA SRL
Nasal spray formulation and method
InactiveUS20060008420A1Prevent signAvoid symptomsOrganic active ingredientsPeptide/protein ingredientsCyclodextrinNasal spray
Owner:BALANCE PHARMA
On-off total saponin as well as its extracting method and application
ActiveCN101161251AGood treatment effectIncrease carotid flowAntipyreticAnalgesicsCervical spondylosisArthritis
A dipsacus root total saponin is disclosed in the present invention, its weight percent accounts for 60 percent to 95 percent of dipsacus root medicinal materials extraction gross, and in dipsacus root total saponin 3-O-alpha-L-arabinopyranosyl-hederagenin-28-O-beta-D-glucopyranosyl(1-6)-beta-D-glucopyranoside accounts for 30 percent to 90 percent of dipsacus root medicinal materials extraction. A dipsacus root extracting method and its application in preparing medicine for treating cervical vertebra, arthritis, hyperosteogeny or osteoporosis are also disclosed in the present invention. By researching pharmacologic effect of the dipsacus root total saponin, finding that the dipsacus root total saponin prepared by the present invention has obvious anti-inflammation, pain-relieving, increasing carotid blood flow and decreasing blood viscosity, treating oestrogen deficiency type osteoporosis function, and has obvious prevention and cure for experimental cervical spondylosis, arthritis, hyperosteogeny or osteoporosis.
Owner:GUANGZHOU BOJI MEDICINE SERVICES
Use of a Lignan for the Manufacture of a Composition for Preventing or Alleviating of Symptoms Relating to Estrogen Deficiency
InactiveUS20080057140A1Preventing and alleviating of symptomImprove the level ofBiocideNervous disorderEnterolactoneMetabolite
The use of a lignan, which is a plant lignan, a metabolite thereof or a combination of both, for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency in an individual. Also disclosed is the use of a plant lignan capable of being a precursor for enterolactone or another metabolite of the plant lignan, for the manufacture of a composition useful for increasing the level of enterolactone or another metabolite of a plant lignan in an individual's serum, where the individual suffers from or is at risk of estrogen deficiency.
Owner:HORMOS MEDICAL OY LTD
Estrogen compositions and therapeutic methods of use thereof
InactiveUS20070036848A1Provide benefitsOrganic active ingredientsUrinary disorderIntravaginal administrationGynecology
A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least one estrogenic compound is present in an amount of about 5 to about 1000 μg estradiol equivalent per unit dose of the composition, and upon application of the composition to the vulvovaginal surface the at least one estrogenic compound is released over a period of about 3 hours to about 30 days. The composition is useful for vulvovaginal administration to treat atrophic vaginitis or a disorder associated therewith, for example in a menopausal or postmenopausal woman. A method for treating a hypoestrogenism-related condition of the urogenital system of a female patient comprises intravaginal administration of at least one estrogenic compound according to a treatment regimen wherein a series of compositions releasing a progressively increasing daily amount of the at least one estrogenic compound is administered over a period of at least about 1 month.
Owner:DRAGTEK CORP
Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
ActiveUS20150133413A1Reduces or prevents such cancer growth inducing cellular activitiesImprove cell activityBiocideOrganic active ingredientsPresent methodAdditive ingredient
Owner:ESTETRA SRL
Pharmaceutical composition comprising esterol derivatives for use in cancer therapy
ActiveUS20060063723A1High affinityIncreased riskOrganic active ingredientsBiocideGynecologyPresent method
The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and / or precursors. The estrogenic component according to the invention does not have undesirable proliferative effects on breast and / or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and / or climacteric complaints.
Owner:ESTETRA SRL
Extractive of total benzofuran of benzoin plants, prepn. method and use thereof
A general benzifuran is extracted from the Styrax plant and can be used to prepared injection, tablet, capsule, etc for preventing and treating early failure of ovary function, climacteric syndrome, osteoporosis, polycystic overy syndrome, acyesis, etc. Its preparing process is also disclosed.
Owner:CHENGDU DIAO PHARMA GROUP
Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
The subject invention provides a use of tibolone and a SERM for the manufacture of a medicine for the treatment of an estrogen-deficiency related complaint and for the prevention of a recurrence of breast cancer in females suffering from, or at risk for breast cancer that exhibit the estrogen-deficiency related complaint.
Owner:AKZO NOBEL NV
Phenylindole compound and preparation method and application thereof
ActiveCN105732465AEasy to prepareHigh yieldOrganic chemistryDigestive systemHormone Receptor ModulatorsHectic fever
The invention belongs to the technical field of medicines, and relates to a phenylindole derivative and application thereof.The phenylindole derivative comprises stereisomer and pharmaceutically-applicable salt of a phenylindole compound and has the structural formula (please see the formula in the description).The phenylindole derivative and the acid-added pharmaceutically-applicable salt of the phenylindole compound can be used in cooperation with existing medicines or used independently as an estrogen receptor regulator for treating or preventing various diseases related to estrogen functions such as bone loss, fractures, bone rarefaction, hectic fever, LDL cholesterol level rise, cardiovascular diseases, cognitive deficits, brain degeneration diseases, anxiety, depression caused by estrogen deficiency, sexual dysfunction, hypertension, retinal degeneration, cancers and especially osteoporosis.
Owner:SHENYANG PHARMA UNIVERSITY
1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof
InactiveCN101863903AOrganic active ingredientsNervous disorderHormone Receptor ModulatorsEndometriosis
The invention belongs to the technical field of medicine and relates to a 1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof used as an estrogen receptor, in particular to a 1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and a pharmaceutically acceptable salt, or a stereoisomer thereof and a prodrug as well as a pharmaceutically acceptable vector in compatibility or a diluent used as an estrogen receptor. The structural general formula of the derivative is disclosed in the specification, and in the structural formula, n R1 can be independently selected from a substituted or unsubstituted amido group, and R2 can be independently selected from H or an acetyl group. The derivative can be used for treating and preventing various diseases related to estrogen functions, such as diseases related to estrogen deficiency, estrogen sensitive cancer and hyperplasia, endometriosis, uterus myoma and osteoarthritis. Compounds or compositions of the derivative can also be independently used or combined with progestogen or a hormoneantagonist as a contraceptive.
![1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof](https://images-eureka.patsnap.com/patent_img/b284bd8b-6c50-4c95-b785-fd5f9bb40800/000001.png "1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof")
![1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof](https://images-eureka.patsnap.com/patent_img/b284bd8b-6c50-4c95-b785-fd5f9bb40800/000002.png "1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof")
![1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof](https://images-eureka.patsnap.com/patent_img/b284bd8b-6c50-4c95-b785-fd5f9bb40800/000003.png "1,4-dihydrobithiophene [3', 2': 5, 6] bithiapyran [4, 3-c] pyrazol-3-carboxylic acid derivative and application thereof")
Owner:SHENYANG PHARMA UNIVERSITY
Estrogenic-active compounds and application thereof
The present invention relates to compounds having estrogenic activity selected from the group consisting of Loliolide, (4S,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one, (4R,6S)-4-Hydroxy-6-nonadecyl-tetrahydro-pyran-2-one and analogues thereof. The compounds of the present invention are selective estrogen receptor modulator, which can selectively activate ERβ and simultaneously express high estrogenic activity, and also can be applied as medical or food compositions to improve estrogen deficiency-related symptoms.
Owner:NAT TAIWAN UNIV
Traditional Chinese medicine for preventing estrogen deficiency from causing bone loss and preparation method thereof
ActiveCN103041107AGood curative effectNo obvious side effectsDigestive systemSkeletal disorderMedicinal herbsOestrogen deficiency
The invention relates to a traditional Chinese medicine for preventing estrogen deficiency from causing bone loss. The traditional Chinese medicine is prepared by the following original medicinal materials in parts by weight: 6-12 parts of rehmannia glutinosa, 4-6 parts of rhizoma dioscoreae, 4-6 parts of fructus lycii, 4-6 parts of semen cuscutae, 4-6 parts of colla corni cervi, 4-6 parts of colla plastri testudinis, 4-6 parts of fructus psoraleae, 4-6 parts of rhizoma drynariae, 2-4 parts of cortex eucommiae and 2-3 parts of liquorice. At the same time, the invention provides a preparation method of the traditional Chinese medicine with water extraction and alcohol precipitation. The traditional Chinese medicine takes into account symptoms and root causes all-around and applies tonification and purgation, and has an efficacy of nourishing kidney and strengthening essence and enriching marrow and strengthening bone altogether, so that the purpose of preventing estrogen deficiency from causing bone loss is achieved. The water extraction and alcohol precipitation is adopted by the preparation method of the traditional Chinese medicine to extract active ingredients and removing inactive ingredients in the original medicinal materials, and furthermore, the efficacy of the medicines is increased. The medicine has no obvious toxic and side effects and no obvious taboo when administrating.
Owner:INST OF BASIC MEDICINE OF SAMS
Aromatase activating agent
Owner:KAO CORP
Piperazinyl-containing indole derivatives, and preparation method and application thereof
ActiveCN105859606AEasy to prepareHigh yieldOrganic active ingredientsOrganic chemistryHormone Receptor ModulatorsHectic fever
The invention belongs to the technical field of medicine, and relates to piperazinyl-containing indole derivatives and medical application thereof. The phenyl indole derivatives comprise stereomers and pharmaceutically applicable salts of the compounds, and the structural general formula is disclosed in the specification. The piperazinyl-containing indole derivatives and pharmaceutically applicable acid-added salts of the compounds can be mixed with the existing drug or independently used as an estrogen receptor regulator for treating or preventing various estrogen-function-related diseases, such as bone loss, fracture, osteoporosis, hectic fever, LDL cholesterol level increase, cardiovascular diseases, cognitive impairment, brain degeneration diseases, anxiety, depression caused by deficiency of estrogen, sexual disorder, hypertension, retinosis and cancer, and especially osteoporosis.
Owner:SHENYANG PHARMA UNIVERSITY
Pentacyclic oxepines and derivatives thereof, compositions and methods
The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC—OCO(C1-C6 alkyl), or —OSO2(C2-C6 alkyl); R0, R2 and R3 are each independently —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), —OSO2(C2-C6 alkyl)or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3 X is —S— or —HC═H—; G is —O—, —S—, —SO—, SO2, or —N(R5)—, wherein R5 is —H or C1-C4 alkyl; and Y is —O—, —S—, —NH—, —NMe—, or —CH2—; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
Owner:ARRAY BIOPHARMA +1
Application of oltipraz in preparation of product for preventing and treating osteoporosis
InactiveCN112972475AAvoid absorptionPromote formationOrganic active ingredientsSkeletal disorderVitamin receptorVitamin D Receptor Deficiency
The invention discloses an application of oltipraz in preparation of a product for preventing and treating osteoporosis. The application comprises any one of the following items: 1) preparing a product for preventing and treating osteoporosis caused by lack of active vitamin D; 2) preparing a product for preventing and treating osteoporosis caused by estrogen deficiency; and 3) preparing a product for preventing and treating osteoporosis caused by vitamin D receptor deficiency. According to the invention, through a test of supplementing an Nrf2 agonistoltiprazto a mouse model, the effect and related mechanism of oltipraz in preventing and treating osteoporosis caused by lack of active vitamin D are disclosed, and meanwhile, experimental and theoretical bases are provided for the application of oltipraz in preventing and treating osteoporosis caused by estrogen deficiency.
Owner:南京医科大学友谊整形外科医院有限责任公司
Application of Eryngiolide A in medicines curing rarefaction of bone caused by lack of antiestrogen
The invention discloses a new use of Eryngiolide A for curing rarefaction of bone. The rarefaction of bone is an important disease damaging human health, with aging of population, rarefaction of bone patients gradually increase, the rarefaction of bone causes huge burden on society, medical treatment and economy. Although relative experts and scholars at home and abroad attach great importance to prevent and cure the rarefaction of bone, the rarefaction of bone still lacks effective curing medicines. The fact that the Eryngiolide A has evident rarefaction of bone resisting function is discovered through in vivo test. Experiment results show that the Eryngiolide A can inhibit strengthening of bone conversion rate caused by ovariectomizing, reduce bone destruction, meanwhile can improve blood calcium concentration, and is benefit for deposition of bones. The Eryngiolide A has therapeutic effect on the deposition of rarefaction of bone caused by lack of the antiestrogen, and has no estrogen side effect.
Owner:吴俊华
Application of punicalagin in preparing medicine for preventing and curing postmenopausal osteoporosis
InactiveCN110711201AOsteoclast activation inhibitionOrganic active ingredientsSkeletal disorderPunicalaginOestrogen deficiency
The invention discloses application of punicalagin in preparing the medicine for preventing and curing postmenopausal osteoporosis, and further discloses a pharmaceutic preparation for preventing andcuring postmenopausal osteoporosis. The therapeutic action of punicalagin (PUN) on osteoporosis of ovariectomized mice is observed by applying the ovariectomized mouse osteoporosis model, the changesof the key indicators, including RANKL and CTSK, of osteoclast activation are evaluated, various indexes of osteoporosis are analyzed, and then therapeutic action mechanism of PUN on estrogen deficiency osteoporosis can be explained. According to the therapeutic action mechanism, after menopause, because of estrogen deficiency, the expression of RANKL can be up-regulated by bone resorption factors, the RANKL path is activated, osteoclasts are activated as a result, and at present, the mechanism is the important one of causing postmenopausal osteoporosis; and the application of PUN is a new wayfor preventing and curing postmenopausal osteoporosis because PUN can inhibit the path and thereby inhibiting osteoclast activation.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
Piperazinone compounds and application thereof
ActiveCN105801564AEasy to prepareHigh yieldOrganic active ingredientsOrganic chemistryHormone Receptor ModulatorsHectic fever
The invention belongs to the technical field of medicine and relates to 1-ethyl-4-[4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1H-indole-1-yl]butyl]piperazine-2,3-dione as well as a medical application, a stereoisomer and pharmaceutically acceptable salt thereof. The structural formula of 1-ethyl-4-[4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1H-indole-1-yl] butyl]piperazine-2,3-dione is represented in the specification; 1-ethyl-4-[4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1H-indole-1-yl]butyl]piperazine-2,3-dione and pharmaceutically acceptable acid addition salt of the compound can be combined with existing drugs or can be independently used as an estrogen receptor modulator for treating or preventing various estrogen function related diseases such as bone loss, fracture, osteoporosis, hectic fever, LDL cholesterol level rise, cardiovascular disease, cognitive impairment, brain degeneration disease and anxiety, as well as depression, sexual dysfunction, hypertension, retinal degeneration and cancer caused by estrogen deficiency, especially osteoporosis.
Owner:SHENYANG PHARMA UNIVERSITY
A composition for treating one or more estrogen related diseases
ActiveUS20210052692A1Reduce and prevent likelihoodPeptide/protein ingredientsEndocrine system disorderDiseaseSide effect
The present invention relates to treating one or more estrogen related diseases while preventing or reducing the likelihood of developing estrogen deficiency related side effects, wherein said composition comprises administering a therapeutically effective amount of a Gn RH antagonist to a patient in need of said treatment, and wherein said amount of Gn RH antagonist is sufficient for providing a mean endogenous serum estradiol level of between about 20 pg / ml and 60 pg / ml, preferably between 30 pg / ml and 50 pg / m, in said patient in a treatment period of at least four weeks, without relying on “add-back” therapy. Said composition and method is simple, effective and will accordingly both increase patient acceptance and compliance of therapy.
Owner:LIFEARC
Composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs
InactiveUS20060051433A1Increase secretionLess adverse effectOrganic active ingredientsBiocideNatural sourcePhlomis umbrosa
The present invention relates to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs, more particularly; to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs in postmenopausal women comprising one or more of Platycodi Radix and Cynanchum wilfordii extract and / or Phlomis umbrosa extract. The present invention provides a composition, a pharmaceutical composition and a food composition capable of replacing estrogen, which comprise one or more selected from the group consisting of Platycodi Radix extract and Cynanchum wilfordii extract and / or Phlomis umbrosa extract. The composition of this invention comprised of the extracts of natural source shows little or no adverse effects such as cancer occurrence compared with estrogen-replacing agent used for conventional hormone replacement therapy; in addition, it has excellent effect on the regeneration and proliferation of tissue cells of female sexual organs, so that it is applicable to treatment of various disorders and diseases developed in postmenopausal women who are deficient in estrogen. Moreover, the composition of this invention has little impurities and high amount of active ingredients.
Owner:NATURALENDO TECH
Oleanol type benzofuran and its glucoside applied in preparation of anti female hormone deficiency medicine
Owner:CHENGDU DIAO PHARMA GROUP
Composition for treating one or more estrogen related diseases
ActiveUS11446351B2Reduce and prevent likelihoodPeptide/protein ingredientsEndocrine system disorderDiseaseSide effect
Owner:LIFEARC
9-alpha-substituted estratrienes as selectively active estrogens
InactiveCN1293090CWith mechanical propertiesOrganic active ingredientsNervous disorderDiseaseEstrogen receptor
This invention describes the new 9alpha-substituted estratrienes of general formula (I) in which R3, R7, R7', R13, R16 as well as R17 and R17' have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
Owner:BAYER IP GMBH
Application of tormentic acid in preparation of medicine for treating or preventing Alzheimer disease caused by estrogen lack
ActiveCN105106222AImprove cognitive impairmentIncrease the number ofOrganic active ingredientsNervous disorderCholinergic cellsDuring menopause
The invention discloses application of tormentic acid in preparation of medicine for treating or preventing the Alzheimer disease caused by estrogen lack, and belongs to the technical field of tormentic acid medicine new application. According to the technical scheme, the application is characterized in that the molecular formula of the tormentic acid is C30H48O5, and the structural formula is as shown in specifications; the tormentic acid can improve the cognition impairment of an AD patient and increase the number of in-brain cholinergic neurons and has a neuron protection effect on CNS, wherein the protection effect can be achieved through ERalpha, and the result provides experimental bases for using the tormentic acid as a medicine select for treating menopause women in combination with AD.
Owner:XINXIANG MEDICAL UNIV
18-nor steroids as selectively active estrogens
This invention describes the new 18-nor steroids (gonatrienes) of general formula (I), in which R1, R2, R3, R6, R7, R8, R9, R11, R11′, R14, R15, R15, R16, R17 and R17′ have the meanings that are indicated in the description, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo a preferential action on bone in comparison to the uterus, and / or pronounced action relative to the stimulation of the expression of 5HT2a-receptors and transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention further describes the use of steroids, on which the gonatriene skeleton is based, for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of the gonatriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bone in comparison to the uterus.
Owner:BAYER SCHERING PHARMA AG
Application of radix angelicae dahuricae extract in aspect of regulating climacteric dyslipidemia
The invention relates to the field of medicine preparation, in particular to application of a radix angelicae dahuricae extract in the aspect of regulating climacteric dyslipidemia. Through exploration, the inventor finds that the angelica dahurica extract can be used for regulating climacteric dyslipidemia, and a new medicament is provided for lipid metabolism disorder caused by estrogen deficiency. Specifically, the radix angelicae dahuricae extract can significantly up-regulate gene expression of HMG-CoA reductase (HMGCR) and cytochrome P450 7A1(CYP7A1) in intestinal liver circulation, and regulate gene expression of related receptors and proteins. The radix angelicae dahuricae extract can reduce the levels of total cholesterol (TC) and triglyceride (TG) of serum and liver, and can relieve fatty degeneration and inflammation of the liver. The radix angelicae dahuricae extract can remarkably regulate the composition of OVX intestinal microorganisms, remarkably improve the activity of bile salt hydrolase (BSH) and reconstruct an SCFA spectrum and a cholic acid metabolic spectrum.
Owner:SHAANXI UNIV OF CHINESE MEDICINE
Indole derivatives containing piperazinyl group and its preparation method and application
ActiveCN105859606BEasy to prepareHigh yieldOrganic active ingredientsOrganic chemistryBrain degenerationFracture osteoporosis
Owner:SHENYANG PHARMA UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com